Diagnosis and treatment of acquired coronary artery disease in adults

Postgraduate Medical Journal

Volumn 85, Issue 1005, 2009, Pages 364-375

  Wilson, J M ^a  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; HEPARIN DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; IVABRADINE; MORPHINE SULFATE; NARCOTIC ANALGESIC AGENT; NIFEDIPINE; NITRATE; PRASUGREL; RADIOPHARMACEUTICAL AGENT; RANOLAZINE; THIENOPYRIDINE DERIVATIVE; THROMBIN INHIBITOR; TICLOPIDINE; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ASTHMA; ATHEROSCLEROSIS; BLOOD CLOT LYSIS; BRADYCARDIA; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DISEASE COURSE; DIZZINESS; DRUG INDUCED HEADACHE; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EMOTIONAL STRESS; EXERCISE TEST; FATIGUE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART SCINTISCANNING; HUMAN; HYPOGLYCEMIA; LABORATORY TEST; LIFESTYLE MODIFICATION; NIGHTMARE; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS CORONARY INTERVENTION; PHYSICAL EXAMINATION; RAYNAUD PHENOMENON; REVIEW; SEXUAL DYSFUNCTION; STABLE ANGINA PECTORIS; THORAX PAIN; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSTABLE ANGINA PECTORIS; VASOSPASM;

ADULT; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; CORONARY ARTERY BYPASS; CORONARY DISEASE; DIAGNOSTIC IMAGING; EXERCISE TEST; HUMANS; PHYSICAL EXAMINATION;

EID: 67650550630     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2008.068791     Document Type: Review

References (81)

1. American Heart Association. Heart disease and stroke statistics - 2004 update. Dallas, Texas: American Heart Association, 2003.
2. Arias E, Anderson RN, Kung HC, et al. Deaths: final data for 2001. Natl Vital Stat Rep 2003;52:1-115.
3. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study. JAMA 1986;256:2835-2838
4. Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham study. Am J Cardiol 1976;38:46-51.
5. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035-2038
6. Morrow K, Morris CK, Froelicher VF, et al. Prediction of cardiovascular death in men undergoing noninvasive evaluation for coronary artery disease. Ann Intern Med 1993;118:689-695 (Pubitemid 23118039)
7. Myers RH, Kiely DK, Cupples LA, et al. Parental history is an independent risk factor for coronary artery disease: the Framingham study. Am Heart J 1990;120:963-969 (Pubitemid 20346165)
8. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847 (Pubitemid 28213628)
9. Canto JGFC, Kiefe CI, Allison JJ, et al. Atypical presentations among Medicare beneficiaries with unstable angina pectoris. Am J Cardiol 2003;91:118-119
10. Douglas PS, Ginsburg GS. The evaluation of chest pain in women. N Engl J Med 1996;334:1311-1315
11. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation 1995;91:1659-1668
12. Wallentin L, Lagerqvist B, Husted S, et al, for the FRISC II Investigators. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronaryartery disease: The FRISC II invasive randomised trial. Lancet 1999;356:9-16.
13. Hammermeister KE, DeRouen TA, Dodge HT. Variables predictive of survival in patients with coronary disease. Selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations. Circulation 1979;59:421-430
14. Margolis JR, Kannel WS, Feinleib M, et al. Clinical features of unrecognized myocardial infarction-silent and symptomatic. Eighteen year follow-up: the Framingham study. Am J Cardiol 1973;32:1-7.
15. Morris CK, Morrow K, Froelicher VF, et al. Prediction of cardiovascular death by means of clinical and exercise test variables in patients selected for cardiac catheterization. Am Heart J 1993;125:1717-1726 (Pubitemid 23169489)
16. Sigurdsson E, Thorgeirsson G, Sigvaldason H, et al. Unrecognized myocardial infarction: epidemiology, clinical characteristics, and the prognostic role of angina pectoris. The Reykjavik study. Ann Intern Med 1995;122:96-102.
17. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (committee to update the 1997 exercise testing guidelines). J Am Coll Cardiol 2002;40:1531-1540
18. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee on management of acute myocardial infarction). J Am Coll Cardiol 1999;34:890-911. (Pubitemid 29436200)
19. Antman EM, Cohen M, Bernink PJLM, et al. The TIMI risk score for unstable angina/ non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000;284:835-842 (Pubitemid 30643610)
20. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an Intravenous NPA for Treatment of Infarcting Myocardium Early II Trial substudy. Circulation 2000;102:2031-2037 (Pubitemid 30786479)
21. Mark DB, Shaw L, Harrell FE Jr, et al. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. N Engl J Med 1991;325:849-853
22. Abbas NA, John RI, Webb MC, et al. Cardiac troponins and renal function in nondialysis patients with chronic kidney disease. Clin Chem 2005;51:2059-2066 (Pubitemid 41532621)
23. de Filippi CR, Thorn EM, Aggarwal M, et al. Frequency and cause of cardiac troponin T elevation in chronic hemodialysis patients from study of cardiovascular magnetic resonance. Am J Cardiol 2007;100:885-889 (Pubitemid 47268284)
24. Montagnana M, Lippi G, Salvagno GL, et al. Reference ranges and diagnostic thresholds of laboratory markers of cardiac damage and dysfunction in a population of apparently healthy black africans. Clin Chem Lab Med 2008;46:714-716 (Pubitemid 351749112)
25. Montagnana M, Lippi G, Tessitore N, et al. Effect of hemodialysis on traditional and innovative cardiac markers. J Clin Lab Anal 2008;22:59-65. (Pubitemid 351272482)
26. Petrovic D, Obrenovic R, Stojimirovic B. Cardiac troponins and left ventricular hypertrophy in hemodialysis patients. Clin Lab 2008;54:145-152
27. Wallace TW, Abdullah SM, Drazner MH, et al. Prevalence and determinants of troponin T elevation in the general population. Circulation 2006;113:1958-1965 (Pubitemid 43754198)
28. Needham DM, Shufelt KA, Tomlinson G, et al. Troponin I and T levels in renal failure patients without acute coronary syndrome: a systematic review of the literature. Can J Cardiol 2004;20:1212-1218 (Pubitemid 39545556)
29. Jarvisalo MJ, Harmoinen A, Hakanen M, et al. Elevated serum C-reactive protein levels and early arterial changes in healthy children. Arterioscler Thromb Vasc Biol 2002;22:1323-1328 (Pubitemid 34875744)
30. Kavey RE, Daniels SR, Lauer RM, et al. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation 2003;107:1562-1566 (Pubitemid 36378499)
31. Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC committee to revise the 1995 guidelines for the clinical use of cardiac radionuclide imaging). J Am Coll Cardiol 2003;42:1318-1333
32. Bruschke AV, Proudfit WL, Sones FM Jr. Clinical course of patients with normal, and slightly or moderately abnormal coronary arteriograms. A follow-up study on 500 patients. Circulation 1973;47:936-945
33. Emond M, Mock MB, Davis KB, et al. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) registry. Circulation 1994;90:2645-2657
34. Ringqvist I, Fisher LD, Mock M, et al. Prognostic value of angiographic indices of coronary artery disease from the Coronary Artery Surgery Study (CASS). J Clin Invest 1983;71:1854-1866.
35. Greenland P, LaBree L, Azen SP, et al. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 2004;291:210-215 (Pubitemid 38082815)
36. Fukuda T, Akagi T, Ishibashi M, et al. Noninvasive evaluation of myocardial ischemia in Kawasaki disease: comparison between dipyridamole stress thallium imaging and exercise stress testing. Am Heart J 1998;135:482-487 (Pubitemid 28125685)
37. Kim WY, Danias PG, Stuber M, et al. Coronary magnetic resonance angiography for the detection of coronary stenoses. N Engl J Med 2001;345:1863-1869 (Pubitemid 33716560)
38. Gerber BL, Garot J, Bluemke DA, et al. Accuracy of contrast-enhanced magnetic resonance imaging in predicting improvement of regional myocardial function in patients after acute myocardial infarction. Circulation 2002;106:1083-1089 (Pubitemid 34970848)
39. Ramani K, Judd RM, Holly TA, et al. Contrast magnetic resonance imaging in the assessment of myocardial viability in patients with stable coronary artery disease and left ventricular dysfunction. Circulation 1998;98:2687-2694 (Pubitemid 28564003)
40. Reimer KA, Rasmussen MM, Jennings RB. On the nature of protection by propranolol against myocardial necrosis after temporary coronary occlusion in dogs. Am J Cardiol 1976;37:520-527
41. Herlitz J, Elmfeldt D, Hjalmarson A, et al. Effect of metoprolol on indirect signs of the size and severity of acute myocardial infarction. Am J Cardiol 1983;51:1282-1288 (Pubitemid 13133066)
42. Tardif JC, Ponikowski P, Kahan T. Efficacy of the IF current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4 month, randomized, placebo-controlled trial. Eur Heart J 2009;30:524-525
43. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 2006;92(suppl IV):iv6-14. (Pubitemid 43974036)
44. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004;291:309-316 (Pubitemid 38101603)
45. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-239 (Pubitemid 38924592)
46. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153
47. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450-1456
48. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906 (Pubitemid 37409706)
49. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106. (Pubitemid 24052591)
50. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983;309:396-403.
51. Feldman M, Cryer B. Aspirin absorption rates and platelet inhibition times with 325- mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution. Am J Cardiol 1999;84:404-409 (Pubitemid 29398659)
52. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-Essence meta-analysis. Circulation 1999;100:1602-1608
53. Antman EM, McCabe CH, Braunwald E. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-st-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis In Myocardial Infarction. Am Heart J 2002;143:229-234
54. Oler A, Whooley MA, Oler J, et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996;276:811-815 (Pubitemid 26301581)
55. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. (Pubitemid 32758501)
56. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015 (Pubitemid 350106708)
57. Karvouni E, Katritsis DG, Ioannidis JP. Intravenous glycoprotein IIB/IIIA receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 2003;41:26-32. (Pubitemid 36044399)
58. Boersma E, Akkerhuis KM, Theroux P, et al. Platelet glycoprotein IIB/IIIA receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation 1999;100:2045-2048 (Pubitemid 29532053)
59. Bhatt DL. Resisting the temptation to oversimplify antiplatelet resistance J Am Coll Cardiol Intv 2008;1:660-662
60. Hachamovitch R, Hayes SW, Friedman JD, et al. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003;107:2900-2907 (Pubitemid 36736630)
61. Fraker TD Jr, Fihn SD, Gibbons RJ, et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. Circulation 2007;116:2762-2772 (Pubitemid 350291248)
62. Anon. Eleven-year survival in the veterans administration randomized trial of coronary bypass surgery for stable angina. The Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group. N Engl J Med 1984;311:1333-1339
63. Hultgren HN, Peduzzi P, Detre K, et al. The 5 year effect of bypass surgery on relief of angina and exercise performance. Circulation 1985;72:V79-83. (Pubitemid 16126349)
64. Peduzzi P, Detre K, Murphy ML, et al. Ten-year incidence of myocardial infarction and prognosis after infarction. Department of Veterans Affairs Cooperative Study of Coronary Artery Bypass Surgery. Circulation 1991;83:747-755
65. Anon. Long-term results of prospective randomised study of coronary artery bypass surgery in stable angina pectoris. European Coronary Surgery Study Group. Lancet 1982;2:1173-1180
66. Anon. Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Survival data. Circulation 1983;68:939-950
67. Detre K, Peduzzi P, Murphy M, et al. Effect of bypass surgery on survival in patients in low- and high-risk subgroups delineated by the use of simple clinical variables. Circulation 1981;63:1329-1338 (Pubitemid 11120670)
68. Takaro T, Hultgren HN, Lipton MJ, et al. The VA Cooperative Randomized Study of Surgery for Coronary Arterial Occlusive Disease II. Subgroup with significant left main lesions. Circulation 1976;54:III107-17.
69. Anon. Myocardial infarction and mortality in the coronary artery surgery study (CASS) randomized trial. N Engl J Med 1984;310:750-758 (Pubitemid 14161407)
70. Peduzzi P, Kamina A, Detre K. Twenty-two-year follow-up in the VA Cooperative Study of Coronary Artery Bypass Surgery for Stable Angina. Am J Cardiol 1998;81:1393-1399 (Pubitemid 28283817)
71. Cameron A, Davis KB, Green GE, et al. Clinical implications of internal mammary artery bypass grafts: the Coronary Artery Surgery Study experience. Circulation 1988;77:815-819 (Pubitemid 18093502)
72. Fiore AC, Naunheim KS, McBride LR, et al. Fifteen-year follow-up for double internal thoracic artery grafts. Eur J Cardiothorac Surg 1991;5:248-252
73. Galbut DL, Traad EA, Dorman MJ, et al. Twelve-year experience with bilateral internal mammary artery grafts. Ann Thorac Surg 1985;40:264-270 (Pubitemid 15227484)
74. Loop FD, Lytle BW, Cosgrove DM, et al. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med 1986;314:1-6. (Pubitemid 16183061)
75. Khot UN, Friedman DT, Pettersson G, et al. Radial artery bypass grafts have an increased occurrence of angiographically severe stenosis and occlusion compared with left internal mammary arteries and saphenous vein grafts. Circulation 2004;109:2086-2091 (Pubitemid 38620216)
76. McGrath PD, Malenka DJ, Wennberg DE, et al. Changing outcomes in percutaneous coronary interventions: a study of 34,752 procedures in Northern New England, 1990 to 1997. Northern New England Cardiovascular Disease Study Group. J Am Coll Cardiol 1999;34:674-680
77. Villareal RP, Lee VV, Elayda MA, et al. Coronary artery bypass surgery versus coronary stenting: risk-adjusted survival rates in 5,619 patients. Tex Heart Inst J 2002;29:3-9. (Pubitemid 34415215)
78. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimuseluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780 (Pubitemid 34586912)
79. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323 (Pubitemid 37186209)
80. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231 (Pubitemid 38067635)
81. Laham RJ, Carrozza JP, Berger C, et al. Long-term (4- to 6-year) outcome of Palmaz- Schatz stenting: paucity of late clinical stent-related problems. J Am Coll Cardiol 1996;28:820-826 (Pubitemid 26348142)